Ipsen announces the co-option of Pascal Touchon as an independent director on its Board of Directors, effective October 4, following Paul Sekhri's decision to step down on the same date due to other professional commitments.

This appointment will be effective for the remainder of Paul Sekhri's term of office, until the 2026 AGM. Pascal Touchon will be a member of the Appointments Committee, the Innovation and Development Committee and the Audit Committee.

Currently CEO of Atara Biotherapeutics, Pascal Touchon has previously held several management positions at Novartis and Servier, and has also served on the boards of various biotech companies.

Copyright (c) 2023 CercleFinance.com. All rights reserved.